NASDAQ:BTAI

BioXcel Therapeutics Competitors

$35.07
-0.80 (-2.23 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.31
Now: $35.07
$35.70
50-Day Range
$34.69
MA: $44.73
$56.98
52-Week Range
$21.56
Now: $35.07
$71.50
Volume281,136 shs
Average Volume584,622 shs
Market Capitalization$861.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.31

Competitors

BioXcel Therapeutics (NASDAQ:BTAI) Vs. IMAB, NKTR, APLS, PTCT, ACAD, and CCXI

Should you be buying BTAI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to BioXcel Therapeutics, including I-Mab (IMAB), Nektar Therapeutics (NKTR), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), and ChemoCentryx (CCXI).

I-Mab (NASDAQ:IMAB) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares I-Mab and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
I-MabN/AN/AN/A
BioXcel TherapeuticsN/A-74.22%-64.31%

Institutional and Insider Ownership

16.6% of I-Mab shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for I-Mab and BioXcel Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
I-Mab00403.00
BioXcel Therapeutics001103.00

I-Mab presently has a consensus target price of $70.00, indicating a potential upside of 46.26%. BioXcel Therapeutics has a consensus target price of $101.8182, indicating a potential upside of 190.33%. Given BioXcel Therapeutics' higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than I-Mab.

Valuation and Earnings

This table compares I-Mab and BioXcel Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$4.31 million798.93$-208,560,000.00($28.90)-1.66
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.36

BioXcel Therapeutics has lower revenue, but higher earnings than I-Mab. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than I-Mab, indicating that it is currently the more affordable of the two stocks.

Summary

BioXcel Therapeutics beats I-Mab on 6 of the 10 factors compared between the two stocks.

Nektar Therapeutics (NASDAQ:NKTR) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares Nektar Therapeutics and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nektar Therapeutics-269.05%-30.74%-22.63%
BioXcel TherapeuticsN/A-74.22%-64.31%

Volatility & Risk

Nektar Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Institutional and Insider Ownership

95.3% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 3.0% of Nektar Therapeutics shares are held by insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Nektar Therapeutics and BioXcel Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nektar Therapeutics$114.62 million29.71$-440,670,000.00($2.52)-7.41
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.36

BioXcel Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Nektar Therapeutics and BioXcel Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nektar Therapeutics16102.00
BioXcel Therapeutics001103.00

Nektar Therapeutics presently has a consensus target price of $25.2857, indicating a potential upside of 35.36%. BioXcel Therapeutics has a consensus target price of $101.8182, indicating a potential upside of 190.33%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Nektar Therapeutics.

Summary

BioXcel Therapeutics beats Nektar Therapeutics on 7 of the 13 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Profitability

This table compares Apellis Pharmaceuticals and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
BioXcel TherapeuticsN/A-74.22%-64.31%

Risk and Volatility

Apellis Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Institutional & Insider Ownership

81.2% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 9.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Apellis Pharmaceuticals and BioXcel Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-8.96
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.36

BioXcel Therapeutics is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Apellis Pharmaceuticals and BioXcel Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
BioXcel Therapeutics001103.00

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, indicating a potential upside of 199.63%. BioXcel Therapeutics has a consensus price target of $101.8182, indicating a potential upside of 190.33%. Given Apellis Pharmaceuticals' higher possible upside, research analysts plainly believe Apellis Pharmaceuticals is more favorable than BioXcel Therapeutics.

PTC Therapeutics (NASDAQ:PTCT) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Profitability

This table compares PTC Therapeutics and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PTC Therapeutics-123.19%-76.10%-24.60%
BioXcel TherapeuticsN/A-74.22%-64.31%

Risk and Volatility

PTC Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Institutional & Insider Ownership

48.7% of BioXcel Therapeutics shares are held by institutional investors. 7.0% of PTC Therapeutics shares are held by insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares PTC Therapeutics and BioXcel Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PTC Therapeutics$306.98 million10.80$-251,580,000.00($3.45)-13.66
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.36

BioXcel Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for PTC Therapeutics and BioXcel Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PTC Therapeutics05702.58
BioXcel Therapeutics001103.00

PTC Therapeutics presently has a consensus price target of $64.90, indicating a potential upside of 37.70%. BioXcel Therapeutics has a consensus price target of $101.8182, indicating a potential upside of 190.33%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than PTC Therapeutics.

Summary

BioXcel Therapeutics beats PTC Therapeutics on 10 of the 13 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Profitability

This table compares ACADIA Pharmaceuticals and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ACADIA Pharmaceuticals-63.92%-40.35%-34.72%
BioXcel TherapeuticsN/A-74.22%-64.31%

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Institutional & Insider Ownership

93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares ACADIA Pharmaceuticals and BioXcel Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$339.08 million9.64$-235,260,000.00($1.60)-12.77
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.36

BioXcel Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for ACADIA Pharmaceuticals and BioXcel Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ACADIA Pharmaceuticals012702.37
BioXcel Therapeutics001103.00

ACADIA Pharmaceuticals presently has a consensus price target of $32.7647, indicating a potential upside of 60.38%. BioXcel Therapeutics has a consensus price target of $101.8182, indicating a potential upside of 190.33%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than ACADIA Pharmaceuticals.

Summary

ACADIA Pharmaceuticals beats BioXcel Therapeutics on 7 of the 13 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.

Earnings & Valuation

This table compares ChemoCentryx and BioXcel Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million89.39$-55,490,000.00($0.98)-47.26
BioXcel TherapeuticsN/AN/A$-32,970,000.00($2.02)-17.36

BioXcel Therapeutics has lower revenue, but higher earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ChemoCentryx has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for ChemoCentryx and BioXcel Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx01713.00
BioXcel Therapeutics001103.00

ChemoCentryx presently has a consensus price target of $80.7778, indicating a potential upside of 74.43%. BioXcel Therapeutics has a consensus price target of $101.8182, indicating a potential upside of 190.33%. Given BioXcel Therapeutics' higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than ChemoCentryx.

Institutional & Insider Ownership

80.7% of ChemoCentryx shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares ChemoCentryx and BioXcel Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-58.10%-17.23%-11.07%
BioXcel TherapeuticsN/A-74.22%-64.31%

Summary

ChemoCentryx beats BioXcel Therapeutics on 7 of the 13 factors compared between the two stocks.


BioXcel Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
I-Mab logo
IMAB
I-Mab
1.4$47.86-7.9%$3.44 billion$4.31 million-1.66Increase in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.68-0.3%$3.41 billion$114.62 million-7.53
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$41.59-0.1%$3.34 billionN/A-5.61
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.13-1.0%$3.31 billion$306.98 million-6.74
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.43-0.2%$3.27 billion$339.08 million-11.88
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.31-6.7%$3.23 billion$36.13 million-69.12Unusual Options Activity
News Coverage
Insmed logo
INSM
Insmed
1.2$30.82-2.9%$3.18 billion$136.47 million-11.85
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$85.87-3.0%$3.11 billion$26.52 million-7.57
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.62-3.8%$3.04 billionN/A-56.03
Alkermes logo
ALKS
Alkermes
1.4$18.78-1.3%$2.99 billion$1.17 billion-40.83
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$67.95-0.4%$2.98 billion$421.03 million23.93Analyst Revision
Arvinas logo
ARVN
Arvinas
1.5$60.45-5.0%$2.95 billion$42.98 million-23.61
Organogenesis logo
ORGO
Organogenesis
1.0$22.98-0.6%$2.94 billion$260.98 million-383.00Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$22.17-0.9%$2.92 billion$80.43 million105.58Decrease in Short Interest
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.59-0.3%$2.78 billion$644.77 million-10.36
OPKO Health logo
OPK
OPKO Health
1.9$4.06-3.0%$2.72 billion$901.90 million-22.55
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.43-1.1%$2.63 billion$306.49 million25.20
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.71-0.1%$2.57 billion$60,000.00-9.85News Coverage
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.05-0.5%$2.54 billion$25 million-8.81
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$40.97-3.8%$2.53 billionN/A-22.51
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$39.97-2.0%$2.48 billion$2.11 million-8.65
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.29-1.1%$2.46 billion$182.24 million-8.08
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$144.90-5.9%$2.41 billion$120.28 million-146.36Decrease in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.64-1.3%$2.36 billion$33.94 million-89.03
ALX Oncology logo
ALXO
ALX Oncology
1.9$57.95-10.0%$2.33 billionN/A0.00Increase in Short Interest
Amarin logo
AMRN
Amarin
1.6$5.84-1.5%$2.30 billion$429.76 million-116.78
Xencor logo
XNCR
Xencor
1.2$39.59-2.2%$2.29 billion$156.70 million-28.28News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$44.30-1.2%$2.21 billion$963.01 million13.76News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$30.49-2.7%$2.16 billion$15 million-15.96
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.18-0.3%$2.00 billion$23.90 million-16.26Analyst Revision
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.91-0.8%$1.99 billion$410,000.00-6.07
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$51.89-2.1%$1.94 billionN/A-19.29
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$62.10-10.3%$1.91 billionN/A-26.43Increase in Short Interest
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.62-0.2%$1.89 billionN/A-17.56
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$24.53-3.7%$1.88 billion$103.54 million-18.44News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.0%$1.88 billionN/A-10.57
MORF
Morphic
1.1$57.73-2.8%$1.87 billion$16.98 million-37.01Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.16-2.1%$1.85 billion$34.51 million-17.23
FibroGen logo
FGEN
FibroGen
1.8$19.89-6.6%$1.82 billion$256.58 million-7.62
MacroGenics logo
MGNX
MacroGenics
1.4$30.07-3.6%$1.80 billion$64.19 million-9.61Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.97-0.1%$1.77 billion$14.87 million-14.17Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.77-3.3%$1.73 billion$1.63 billion14.07Decrease in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$23.85-1.3%$1.71 billion$26.87 million-12.49Insider Selling
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$40.42-7.4%$1.66 billionN/A0.00Analyst Report
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.16-0.3%$1.64 billion$428.41 million14.72
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.72-1.4%$1.63 billionN/A0.00
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.64-1.3%$1.61 billion$320,000.00-8.60Analyst Report
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$22.76-5.4%$1.57 billion$2.34 million-9.64
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.